Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $47.39 | 52-week high | $58.69 |
| Prev. close | $47.10 | 52-week low | $5.65 |
| Day low | $46.51 | Volume | 573,988 |
| Day high | $48.23 | Avg. volume | 751,350 |
| 50-day MA | $38.57 | Dividend yield | N/A |
| 200-day MA | $17.05 | Market Cap | 2.45B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Latest JANX News From Around the Web
Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.
An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% UndervaluedKey Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity... |
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsSAN DIEGO, November 07, 2023--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights |
JANX Price Returns
| 1-mo | 24.97% |
| 3-mo | 407.93% |
| 6-mo | 687.21% |
| 1-year | 217.20% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 341.66% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...